CareDx, Inc. (CDNA) vs GRAIL, Inc. (GRAL)

CareDx, Inc. and GRAIL, Inc. are both Diagnostics & Research companies. GRAIL, Inc. is the larger, with a market value of $5.5B against $3.2B — 1.7× the size. GRAIL, Inc. has negative trailing earnings, so its P/E is not meaningful; CareDx, Inc. trades at 29.6×. CareDx, Inc. grew revenue faster over the last twelve months: 34.4% against 23.1%. CareDx, Inc. has the higher net margin (24.2% vs −237.0%) and the higher return on invested capital (130.1% vs −20.8%). Across the 16 metrics below, CareDx, Inc. leads on 12 and GRAIL, Inc. on 4.

Valuation

Metric CDNA GRAL Diagnostics & Research median
P/E 29.62 n/m 33.95
P/S 7.15 33.10 4.87
P/B 7.70 2.15 3.12
Price to free cash flow 39.42 n/m 34.02
EV/EBITDA 22.60 n/m 25.20
EV/Sales 6.42 27.89 5.66
Earnings yield 3.38% (7.68%) (1.75%)
Free cash flow yield 2.54% (5.41%) (0.13%)

Profitability

Metric CDNA GRAL Diagnostics & Research median
Gross margin 70.58% (31.31%) 50.89%
Operating margin 23.61% (338.40%) (8.57%)
Net margin 24.23% (236.95%) (6.37%)
Free cash flow margin 18.49% (179.21%) 0.00%
Return on equity 29.49% (16.12%) (2.92%)
Return on assets 22.72% (14.12%) (6.71%)
Return on invested capital 130.06% (20.79%) 0.00%

Growth

Metric CDNA GRAL Diagnostics & Research median
Revenue growth (TTM) 34.41% 23.07% 7.69%
EPS growth (last fiscal year) (143.01%) 82.51% —
Revenue growth, 5-year CAGR 14.59% — 7.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CDNA GRAL Diagnostics & Research median
Debt to equity 0.00 0.00 0.11
Current ratio 4.58 10.95 2.02
Net debt to EBITDA 19.49 2.27 0.78

Dividend

Metric CDNA GRAL Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 — 0.00

Size

Metric CDNA GRAL Diagnostics & Research median
Market cap 3.18b 5.54b 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack